Pilot trial of albuterol in spinal muscular atrophy

Neurology

Volumn 59, Issue 4, 2002, Pages 609-610

  Kinali, M ^a   Mercuri, E ^a   Main, M ^a   De Biasia, F ^a   Karatza, A ^a   Higgins, R ^a   Banks, L M ^a   Manzur, A Y ^a   Muntoni, Francesco ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; SALBUTAMOL;

ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOSE TIME EFFECT RELATION; DRUG MECHANISM; FEMALE; FORCED EXPIRATORY VOLUME; HAND MOVEMENT; HEART PALPITATION; HUMAN; LEAN BODY WEIGHT; MALE; MUSCLE CRAMP; MUSCLE FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINAL MUSCULAR ATROPHY; STATISTICAL SIGNIFICANCE; TREMOR;

EID: 0037183535     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.59.4.609     Document Type: Article

References (8)

1. Salbutamol, a β-2 adrenoreceptor agonist, increases skeletal muscle strength in young men
2. The effects of albuterol and isokinetic exercise on the quadriceps muscle group
3. Clenbuterol, a β-adrenoreceptor agonist, increases relative muscle strength in orthopaedic patients
4. Randomised, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy
5. Increased muscle strength in paralyzed patients after spinal cord injury: Effect of beta-2 adrenergic agonist
6. Reference values of maximum isometric muscle force obtained in 270 children aged 4-16 years by hand-held dynamometry
7. Natural history in proximal spinal muscular atrophy
8. Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice